{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:59:28Z","timestamp":1777611568879,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017607","name":"Centro de Biolog\u00eda Molecular Severo Ochoa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.neurot.2025.e00706","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:20:22Z","timestamp":1753183222000},"page":"e00706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of efavirenz in Niemann-Pick disease type C"],"prefix":"10.1016","volume":"22","author":[{"given":"Jordi","family":"Gasc\u00f3n-Bayarri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"S\u00e1nchez-Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago","family":"Carnaval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Bejr-Kasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Campdelacreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rodr\u00edguez-Bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Cos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"de Lama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"L\u00f3pez de Munain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idoia","family":"Rouco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"P\u00e9rez-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Cerd\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Muelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Sevillano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Villoria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Videla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00706_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00706_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-5-16","article-title":"Niemann-Pick disease type C","volume":"5","author":"Vanier","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","article-title":"Consensus clinical management guidelines for Niemann-Pick disease type C","volume":"13","author":"Geberhiwot","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib4","first-page":"118","article-title":"Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis","volume":"58","author":"Vanier","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.neurot.2025.e00706_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/mgme.1999.2882","article-title":"Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network","volume":"68","author":"Higgins","year":"1999","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.neurot.2025.e00706_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1073\/pnas.96.3.805","article-title":"Niemann-Pick C1 protein: obligatory roles for N-terminal domains and lysosomal targeting in cholesterol mobilization","volume":"96","author":"Watari","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2025.e00706_bib7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1194\/jlr.R047837","article-title":"Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin","volume":"55","author":"Vance","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.neurot.2025.e00706_bib8","article-title":"Miglustat reverts the impairment of synaptic plasticity in a mouse model of NPC disease","volume":"2016","author":"D'Arcangelo","year":"2016","journal-title":"Neural Plast"},{"key":"10.1016\/j.neurot.2025.e00706_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/gim.2015.25","article-title":"High incidence of unrecognized visceral\/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets","volume":"18","author":"Wassif","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2025.e00706_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","article-title":"Niemann-Pick disease type C","volume":"64","author":"Vanier","year":"2003","journal-title":"Clin Genet"},{"key":"10.1016\/j.neurot.2025.e00706_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10545-014-9794-4","article-title":"Complex lipid trafficking in Niemann-Pick disease type C","volume":"38","author":"Vanier","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1194\/jlr.M500482-JLR200","article-title":"The Niemann-Pick C1 protein in recycling endosomes of presynaptic nerve terminals","volume":"47","author":"Karten","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.neurot.2025.e00706_bib13","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1074\/jbc.M205406200","article-title":"Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons","volume":"278","author":"Karten","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2025.e00706_bib14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1083\/jcb.201407122","article-title":"LTP-triggered cholesterol redistribution activates Cdc42 and drives AMPA receptor synaptic delivery","volume":"208","author":"Brachet","year":"2015","journal-title":"J Cell Biol"},{"key":"10.1016\/j.neurot.2025.e00706_bib15","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1093\/hmg\/dds324","article-title":"Impaired proteolysis underlies autophagic dysfunction in Niemann\u2013Pick type C disease","volume":"21","author":"Elrick","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00706_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126600","article-title":"Neurodegeneration in niemann-pick type C disease: an updated review on pharmacological and non-pharmacological approaches to counteract brain and cognitive impairment","volume":"22","author":"Cariati","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2025.e00706_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbalip.2004.08.011","article-title":"Consequences of NPC1 and NPC2 loss of function in mammalian neurons","volume":"1685","author":"Walkley","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.neurot.2025.e00706_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1196\/annals.1325.041","article-title":"Niemann-Pick type C disease in two affected sisters: ocular motor recordings and brain-stem neuropathology","volume":"1039","author":"Solomon","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2025.e00706_bib19","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0929-693X(10)70012-9","article-title":"[Clinical diagnosis of the adult form of Niemann-Pick type C disease]","volume":"17","author":"Sedel","year":"2010","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.neurot.2025.e00706_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s13311-013-0217-2","article-title":"Treatment of Niemann--Pick type C disease by histone deacetylase inhibitors","volume":"10","author":"Helquist","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00706_bib21","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s11011-021-00842-0","article-title":"Treatment trials in Niemann-Pick type C disease","volume":"36","author":"Sitarska","year":"2021","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.neurot.2025.e00706_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurot.2025.e00706_bib24","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1021\/acs.jmedchem.9b01383","article-title":"In vitro activation of cytochrome P450 46A1 (CYP46A1) by efavirenz-related compounds","volume":"63","author":"Mast","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00706_bib25","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1093\/hmg\/ddu331","article-title":"Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1)","volume":"23","author":"Tortelli","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00706_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.696778","article-title":"Cholesterol hydroxylating cytochrome P450 46A1: from mechanisms of action to clinical applications","volume":"13","author":"Pikuleva","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2025.e00706_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awv384","article-title":"CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease","volume":"139","author":"Boussicault","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00706_bib28","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1093\/hmg\/ddv268","article-title":"Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology","volume":"24","author":"Burlot","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2025.e00706_bib29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/ejn.12911","article-title":"Inhibiting cholesterol degradation induces neuronal sclerosis and epileptic activity in mouse hippocampus","volume":"41","author":"Chali","year":"2015","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurot.2025.e00706_bib30","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/brain\/awv166","article-title":"CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease","volume":"138","author":"Djelti","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00706_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/mt.2009.175","article-title":"Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease","volume":"18","author":"Hudry","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2025.e00706_bib32","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1074\/jbc.M113.532846","article-title":"Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice","volume":"289","author":"Mast","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2025.e00706_bib33","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948143","article-title":"NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP46A1 activation","volume":"20","author":"Mitroi","year":"2019","journal-title":"EMBO Rep"},{"key":"10.1016\/j.neurot.2025.e00706_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-022-01151-z","article-title":"CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease","volume":"14","author":"Lerner","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurot.2025.e00706_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031471","article-title":"Efficacy and safety clinical trial with efavirenz in patients diagnosed with adult Niemann-pick type C with cognitive impairment","volume":"101","author":"Gasc\u00f3n-Bayarri","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.neurot.2025.e00706_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajmg.b.30969","article-title":"Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C","volume":"153B","author":"Yanjanin","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.neurot.2025.e00706_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-006-0384-7","article-title":"The natural history of Niemann-Pick disease type C in the UK","volume":"30","author":"Imrie","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib38","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1212\/WNL.42.12.2286","article-title":"A clinical staging classification for type C Niemann-Pick disease","volume":"42","author":"Higgins","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00706_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10545-006-0417-6","article-title":"Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations","volume":"30","author":"Klarner","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13023-017-0714-1","article-title":"Cognitive impairment profile in adult patients with Niemann pick type C disease","volume":"12","author":"Heitz","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymgme.2009.06.009","article-title":"Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study","volume":"98","author":"Wraith","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.neurot.2025.e00706_bib42","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1007\/s10072-021-05337-5","article-title":"Neuropsychological assessment in Niemann-Pick disease type C: a systematic review","volume":"42","author":"Maresca","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00706_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13023-018-0844-0","article-title":"Miglustat in Niemann-Pick disease type C patients: a review","volume":"13","author":"Pineda","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib44","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0b013e318208f4ab","article-title":"Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study","volume":"76","author":"Mattsson","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00706_bib45","first-page":"45","article-title":"Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C","volume":"3","author":"Mattsson","year":"2012","journal-title":"JIMD Rep"},{"key":"10.1016\/j.neurot.2025.e00706_bib46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2310151","article-title":"Trial of N-Acetyl-l-Leucine in niemann-pick disease type C","volume":"390","author":"Bremova-Ertl","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00706_bib47","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/jimd.12428","article-title":"Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2\/3 trial of a novel treatment","volume":"44","author":"Mengel","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.neurot.2025.e00706_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40263-019-00642-2","article-title":"Long-term neuropsychological outcomes from an open-label phase I\/IIa trial of 2-Hydroxypropyl-beta-Cyclodextrins (VTS-270) in niemann-pick disease, type C1","volume":"33","author":"Farmer","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00706_bib49","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2022.0388","article-title":"Endo-lysosomal dysfunction and neuronal-glial crosstalk in Niemann-Pick type C disease","volume":"379","author":"Malara","year":"2024","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.neurot.2025.e00706_bib50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0895-4356(99)00206-1","article-title":"Methods for assessing responsiveness: a critical review and recommendations","volume":"53","author":"Husted","year":"2000","journal-title":"J Clin Epidemiol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:24:15Z","timestamp":1772760255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1878747925001849"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00706","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of efavirenz in Niemann-Pick disease type C","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00706"}}